Abstract 73P
Background
The number of typical and atypical (defined as mitoses with any morphological appearance other than the typical forms) mitotic figures (MFs) and a high atypical-to-typical mitosis ratio are strongly associated with tumour aggressivity, survival rates, and a predictor of poor response to chemotherapy in breast cancer. Manual detection is time consuming, especially on whole slide images (WSIs). An automated approach is therefore necessary to investigate these aspects on a larger scale. We demonstrate that deep learning can be used to automate this detection, improving on the performance of pathologists.
Methods
All MFs in the mammary carcinoma dataset (21 hematoxylin and eosin (H&E)-stained WSIs with ∼14 000 MFs and ∼36 000 hard negatives) were labelled as typical or atypical. These slides (originally scanned on a Leica scanner) were then rescanned on six other scanners (2x Hammamatsu, 2x 3DHISTECH, Philips, Olympus), and the annotations were registered. This gave a large, multi-scanner dataset, which was used to train a YOLOv6 deep learning object detection model. For testing, all MFs in the (human) TUPAC16 and MIDOG21 datasets were labelled by two pathologists as either typical or atypical. In cases of disagreement, a third reader gave a consensus. We used the alternative version of the TUPAC16 dataset provided by the same authors as the MIDOG21 dataset to reduce potential label bias. We then ran our model on these images and compared the mean average precision (mAP) vs the consensus to the mAPs of the two individual pathologists vs the consensus.
Results
The mAP of our model (0.80) was higher than the average mAP of the two pathologists (0.75, p<0.05), showing that the model can successfully automate the process of MF detection. There was considerable disagreement in the labelling by the two pathologists (14% of cases). By automating the process we reduce this variability, meaning we can more consistently predict clinical outcomes (e.g. survival rates) from our results.
Conclusions
The numbers of both typical and atypical MFs are indicators of patient survival and response to treatment. We have demonstrated an automated deep learning model that can accurately detect these figures and could thus be used for patient survival prediction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tribun.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract